We identified drugs that were significantly more toxic in BL compared to other entities (p < 0.01) including inhibitors of BTK (ibrutinib), CK2 (CX-4945), DNA-PK (NU7441), EGFR (afatinib) and CHK2 (Fig. 1B). This evidence concerns the gene EGFR and Burkitt lymphoma.